Biogen Inc. (BIIB)
| Bid | 116.93 |
| Market Cap | 17.18B |
| Revenue (ttm) | 9.47B |
| Net Income (ttm) | 1.63B |
| EPS (ttm) | 11.18 |
| PE Ratio (ttm) | 10.5 |
| Forward PE | 8.84 |
| Analyst | Hold |
| Ask | 123.13 |
| Volume | 508,056 |
| Avg. Volume (20D) | 2,198,196.3 |
| Open | 116.41 |
| Previous Close | 115.17 |
| Day's Range | 115.66 - 118.61 |
| 52-Week Range | 110.04 - 238.00 |
| Beta | 0.06 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad...
Analyst Forecast
According to 27 analyst ratings, the average rating for BIIB stock is "Hold." The 12-month stock price forecast is $210, which is an increase of 78.92% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)Biogen Inc. (NASDAQ:BIIB ) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Paul Matteis - Stif...
